Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models | Science Translational Medicine
Activating the AHR-ELMSAN1 axis enhances BET therapy and suppresses leukemia stem cells in acute myeloid leukemia.
